Rigel Pharmaceuticals RIGL EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Rigel Pharmaceuticals’s reported figures.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's EBITDA?
- Rigel Pharmaceuticals (RIGL) reported EBITDA of $12.48M in Q1 2026.
- How has Rigel Pharmaceuticals's EBITDA changed year-over-year?
- Rigel Pharmaceuticals's EBITDA decreased by 6.7% year-over-year, from $13.38M to $12.48M.
- What is the long-term trend for Rigel Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's EBITDA has grown at a 83.3% compound annual growth rate (CAGR), from -$11.33M to $127.88M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.